MSD’s Keytruda (pembrolizumab) Receives the NICE Recommendation for the Treatment of Triple-Negative Breast Cancer
Shots:
- NICE has issued the final draft guidance recommending Keytruda (pembrolizumab) with CT that helps to reduce the size of the tumor & brings the therapy as a treatment option for neoadjuvant, and adjuvant treatment after surgery for adults with early TNBC who are at high risk of recurrence, or LA TNBC
- The NICE decision was based on the (KEYNOTE-522) trial that evaluated the safety & efficacy of pembrolizumab + CT vs CT alone in 1174 patients with newly diagnosed, previously untreated, and non-metastatic TNBC
- Additionally, the results showed that the trial met its 1EPs of EFS & pCR along with an improvement in EFS over CT alone after the median follow-up of 39.1mos.
Ref: NICE | Image: MSD
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
